Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
- The Art of Business
September 26, 2011
- Chugai Licenses Melanoma Treatment Vemurafenib from Roche; PI Trial to Begin in 2012
August 29, 2011
- Pfizer Japan Withdraws NDA for Fesoterodine
August 29, 2011
- Switch OTC Versions of Pemirolast K Recommended for Approval
August 29, 2011
- BI Licenses ADCC Enhancing Technology from ProBioGen
August 29, 2011
- Caffeine Citrate Designated as an Orphan Drug
August 29, 2011
- JAMS Opposes Switch OTC Status for 3 Drugs Including Acarbose
August 29, 2011
- Eisai Establishes Marketing Subsidiary in Mexico
August 29, 2011
- JGA to Ask for Retention of “70% Rule”in Pricing of “First Generics”
August 29, 2011
- Mr Wolf of PhRMA Explains Advantages of VICP Introduced in US
August 29, 2011
- Shionogi Acquires 24.17% Stake in C&O of China
August 29, 2011
- Kyowa Pharm. Ind. Seeking M&A to Expand Product Line-up
August 29, 2011
- Saitama Police Send Case to Public Prosecutors Office against President of Saitama Pharm. Association
August 29, 2011
- US Court Orders Actelion to Pay Damages to Asahi Kasei Pharma for Stopping Fasudil's Development
August 29, 2011
- Biosimilars Offer Growth Opportunity: President Sakamoto of Toyobo
August 29, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…